Source: Eur Respir J 2012; 39: 496-498
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Kojonazarov B., Myrzaakhmatova A., Sooronbaev T., Ishizaki T., Aldashev A.. Effects of fasudil in patients with high-altitude pulmonary hypertension. Eur Respir J 2012; 39: 496-498

Member's Comments

No comment yet.

Related content which might interest you: Effect of simvastatin on pulmonary hypertension in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 287s Year: 2007 Effects of sildenafil on secondary pulmonary hypertension in highlanders with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 73s Year: 2007 Effect of normobaric hypoxia on pulmonary hemodynamics in patients with precapillary pulmonary hypertension Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Effects of bosentan in patients with severe pulmonary hypertension and mild-to-moderate COPD Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Effects of nebulised iloprost on pulmonary function and oxygenation in patients with severe pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002 Effect of roflumilast on hypoxia- and monocrotaline-induced pulmonary hypertension in rats Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair Year: 2007 Acute pulmonary vasoreactivity to beraprost in patients with severe pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 597s Year: 2002 Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Acute effects of Sildenafil and Iloprost in pulmonary hypertension of various aetiology Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002 Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003 Effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Effect of fasudil on the bleomycin-induced pulmonary fibrosis and hypertension in mice Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms Year: 2012 Effects of Valsartan on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1 Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil Source: Eur Respir J 2010; 36: 800-807 Year: 2010 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015